CN1853702A - Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method - Google Patents
Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method Download PDFInfo
- Publication number
- CN1853702A CN1853702A CN 200510068659 CN200510068659A CN1853702A CN 1853702 A CN1853702 A CN 1853702A CN 200510068659 CN200510068659 CN 200510068659 CN 200510068659 A CN200510068659 A CN 200510068659A CN 1853702 A CN1853702 A CN 1853702A
- Authority
- CN
- China
- Prior art keywords
- radix
- blood
- parts
- rhizoma atractylodis
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for preventing diabetes and its complication, hyperlipemia, hypertension and cardiovascular disease, and improving blood flow and immunity is prepared from 10 Chinese-medicinal materials including ginseng, wolfberry bark, wolfberry fruit, red sage root, etc through proportional mixing, pulverizing, immersing in water, distilling, and mixing the distilled liquid with the decoction.
Description
1, technical field
The present invention relates to the medicine of a kind of blood sugar lowering, blood fat reducing, blood pressure lowering, raising blood flow and immunity, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.The invention still further relates to the preparation method of this medicine.
2, background technology
Diabetes are the third-largest diseases that jeopardize the human life, serious concurrent hyperlipemia or hypertension etc.Studies show that the patient causes sugar, fat, protein metabolism disorder owing to insulin in the blood lacks relatively or definitely, dysarteriotony causes atherosclerosis and microcirculation disturbance, and hemodynamics changes, fibrinolytic system and platelet function abnormality are assembled, and blood stasis is detained.The traditional Chinese medical science thinks mainly and to belong to categories such as " turbid yin ", " phlegm-damp ", " damp and hot " by due to the deficiency of vital energy, the deficiency of YIN, and the blood stasis due to two void can block mechanism of qi, and body fluid loses in defeated cloth, and multiple complications appears in channels stasis of blood resistance (trunk, little blood vessel, neuropathy).Primary disease is mainly at the heart, liver,spleen,kidney etc.
Both at home and abroad to the primary disease Drug therapy, run into following technical barrier at present:
1. hypoglycemic effect is good for Western medicine class (as two flesh classes, iodine ureas, insulin etc.), but side effect is big, for a long time with infringement liver, kidney and hemocyte, to and issue licence invalid.
2. Chinese patent medicine class blood sugar reducing function is shining slow, and effect is not fairly obvious.
3, summary of the invention:
The purpose of this invention is to provide a kind of blood sugar lowering, blood fat reducing, blood pressure lowering, raising blood flow and immunity, alleviate and prevent and treat the medicine of diabetic complication effect.
Another object of the present invention provides the preparation method of this medicine.
The present invention is to diabetes (diabetes) and pathogenetic understanding of complication and Therapeutic Principle according to Chinese medicine, with reference to modern pharmacological research achievement and advanced technologies, from natural plant, filter out supplementing QI and nourishing YIN, blood sugar lowering, blood fat reducing, blood pressure lowering, blood circulation and channel invigorating, can improve the medical material of blood circulation flow and immunity, by Chinese theoretical prescription, skim the cream off milk with modern advanced technologies, make the integrally-regulated and blood circulation and channel invigorating of its performance, the all methods such as blood flow and immunity that improve cooperate, promote endogenous secretion of insulin, reduce exogenous insulin periphery drag, effective blood sugar regulation, in the time of metabolism disorder of blood lipid, microcirculation improvement is prevented and treated diabetes, hyperlipidemia patient merges cardiovascular pathological changes.
Medicine of the present invention is made (consumption is a weight) by following component:
Radix Ginseng 10-30 part Cortex Lycii 10-25 part Rhizoma Polygonati 20-40 part
Radix Ophiopogonis 10-20 part Fructus Lycii 10-25 part Rhizoma Atractylodis Macrocephalae 10-25 part
Fructus Ligustri Lucidi 15-25 part Radix Et Caulis Acanthopanacis Senticosi 20-50 part Rhizoma Atractylodis 10-20 part
Radix Salviae Miltiorrhizae 10-20 part
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Radix Ginseng 3-10 part Cortex Lycii 6-15 part Rhizoma Polygonati 10-30 part
Radix Ophiopogonis 5-15 part Fructus Lycii 6-15 part Rhizoma Atractylodis Macrocephalae 8-15 part
Fructus Ligustri Lucidi 10-20 part Radix Et Caulis Acanthopanacis Senticosi 10-45 part Rhizoma Atractylodis 5-15 part
Radix Salviae Miltiorrhizae 5-15 part
The optimum weight proportioning of medicine of the present invention is:
13 parts of 8 parts of Rhizoma Polygonatis of 10 parts of Cortex Lycii of Radix Ginseng
8 parts of 8 parts of Rhizoma Atractylodis Macrocephalaes of 10 parts of Fructus Lycii of Radix Ophiopogonis
11 parts of 22 parts of Rhizoma Atractylodis of 10 parts of Radix Et Caulis Acanthopanacis Senticosis of Fructus Ligustri Lucidi
10 parts of Radix Salviae Miltiorrhizaes
Above-mentioned each component is made medicine production method of the present invention is:
(1) above-mentioned prescription medical material mixed powder is broken, make coarse powder, enable pass is crossed the 2-3 sieve, and the water logging that adds 2 times of amounts was steeped 1 hour;
(2) earlier fried with way of distillation processing, distillate with fry in shallow oil soup (filter and remove residue) and preserve respectively;
(3) again medicinal residues are boiled according to a conventional method, fry in shallow oil, fry in shallow oil the soup filter and remove residue, preserve;
(4) also available " multi-function extractor " produced distillate according to a conventional method and fried in shallow oil soup;
(5) distillate is added adjuvant after soup concentrates respectively with frying in shallow oil, be hybridly prepared into mixture;
(6) make the Chinese patent medicine dosage form according to a conventional method again, as hard capsule, soft capsule, tablet, granule, powder, pill, teabag, medicated wine, oral liquid, distillate medicinal water, injection etc.
An important feature of the present invention is to contain terpenes and flavonoid composition in the medicament, terpenes total content 0.5%-1.0%, flavonoid total content 0.9%-1.8%.Wherein the terpenes composition has good blood sugar lowering, cholesterol reducing effect.Contained flavone compound has very strong oxidation resistance, energy vessel softening, reduction vascular fragility, and microcirculation improvement can reduce too high blood fat, blood pressure, treatment of vascular sclerosis.The terpenes flavone compound has remarkable blood sugar decreasing effect, can increase the islets of langerhans blood perfusion, helps the synthetic and secretion of insulin; Platelet aggregation and thrombosis there are the good restraining effect, can blood circulation promoting and blood stasis dispelling, cleaning blood vessel, blood circulation promoting, raising blood flow; Also has the effect of very strong defying age, enhancing body immunity.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
(1) to select the natural edible-plant medicine for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation.Utilize comprehensive function therapy diabetes, hyperlipidemia, the hypertension of various Chinese medicines, nontoxic, harmless to human body.
(2) select for use the way of distillation to extract active ingredient, the drug bioavailability height can reach quick-acting, purpose efficiently.
(3) diabetes and hyperlipidemia complications, hyperpietic there is good prevention effect.
For showing the present invention to the treatment of diabetes effect, through the clinical observation of 200 routine systems, and selection medical history, the state of an illness, age, sex and suitable diabetics 100 examples of former Therapeutic Method are matched group.From being in hospital and endocrine special outpatient clinic selection case, press the diabetes diagnosis standard that WHO1980 formulates, the maturity-onset diabetes patient who makes a definite diagnosis, on the basis of dietetic therapy and medicine (oral antidiabetic drug and insulin) treatment, fasting glucose 7.2mmoI/L person is the object of observation, wherein male 96 examples, women 104 examples, age 27-50 year, course of disease half a year to 20 year.Test group: on former treatment basis, the lipid lowerers of stopping using is obeyed medicine of the present invention.Matched group: blood sugar lowering, blood fat reducing treatment routinely, wherein hypoglycemic medicine, kind instructions about how to take medicine consumption and test group are complementary, and lipid lowerers adopts the import fenofibrate.Adopt same procedure to make regular check on fasting glucose and blood fat, two months observation periods, 20 days is a course of treatment, totally three courses of treatment.
Instructions of taking: oral liquid of the present invention 20ml/ time, day clothes 3 times, ante cibum, boiled water was taken after mixing it with water.Clinical test results such as subordinate list 1-2.
Subordinate list 1 is taken medicine of the present invention front and back insulin, diamicron with being and change of blood sugar
| Case load | Insulin dosage (U/d) | Diamicron consumption (mg/d) | Fasting glucose decline (mmol/L) | |||
| Before | After | Before | After | Before | After | |
| Test group 200 matched groups 100 T P | 46.2 45.89 0.28 ＞0.05 | 20.59 49.18 10.87 ＜0.01 | 260 240 0.26 ＞0.05 | 60 280 8.75 ＜0.01 | 11.7±3.69 11.37±3.18 0.54 ＞0.05 | 7.55±2.32 9.78±3.01 2.46 ＜0.01 |
Subordinate list 2 is taken medicine front and back lipid lowerers consumption of the present invention and the average concentration change of blood fat
| Case load | Sharp flat consumption (U/d) | Serum cholesterol meansigma methods (mg/d) | Serum glycerol meansigma methods (mmol/L) | |||
| Before | After | Before | After | Before | After | |
| Test group 100 matched groups 50 T P | 0 300 | 0 300 | 5.77±1.10 5.87±1.06 0.84 ＞0.05 | 4.52±0.82 5.13±0.97 4.32 ＞0.05 | 2.12±1.07 2.08±0.93 0.76 ＞0.05 | 1.34±0.53 2.51±0.32 3.55 ＞0.05 |
From subordinate list 1 as can be seen, fasting glucose concentration is similar substantially with the hypoglycemic medicine consumption before two groups of tests, P＜0.05, and blood glucose descended after test group was taken the present invention, and the antidiabetic drug consumption is but than original minimizing 1/3-1/2.
Subordinate list 2 data show that serum cholesterol and triglyceride mean concentration do not have significant difference before two groups of tests; But after test group is taken medicine of the present invention, do not use any other lipid lowerers, can reach the blood fat reducing purpose.
Take the relevant data of immunity of organisms before and after the medicine of the present invention, measurement result 3 (matched group is the normal person, and test grade is the diabetes patient) of seeing attached list.
Subordinate list 3T Lymphocyte Subsets Determination result
| The example number | OKT(％) | OKT 4(％) | OKT 3(％) | OKT 4 OKT 3 | ||
| Test group | After treating before the treatment | 50 50 | 64.47±6.23 64.37±7.28 | 36.47±4.27 38.91±4.12 | 31.48±3.68 27.57±4.32 | 1.27±0.14 1.43±0.32 |
| Matched group | 40 | 64.36±8.70 | 38.91±4.11 | 25.43±4.18 | 1.46±0.24 | |
The detection method of T cell subsets is to adopt conventional alkaline phosphorus enzyme alkali resistance phosphoric acid enzyme process.Determination data shows that diabetics is OKT before taking medicine of the present invention
3Be significantly higher than the normal person, OKT
4/ OKT
3Ratio obviously reduces, and takes after the medicine of the present invention, and the two all roughly recovers normal, shows that medicine of the present invention has the enhancing human body immunity function.
Test statistics shows: with medicament of the present invention 200 diabeticss are done therapeutic test, that obtains significant curative effect accounts for 53%, substantially effectively accounts for 42%, and invalid accounts for 5%, and total effective rate reaches 95%.
4, the specific embodiment
Embodiment:
Take by weighing raw material by following proportioning
Radix Ginseng 10kg Cortex Lycii 8kg Rhizoma Polygonati 13kg
Radix Ophiopogonis 8kg Fructus Lycii 8kg Rhizoma Atractylodis Macrocephalae 8kg
Fructus Ligustri Lucidi 10kg Radix Et Caulis Acanthopanacis Senticosi 22kg Rhizoma Atractylodis 11kg
Radix Salviae Miltiorrhizae 10kg
Production method is as follows:
Earlier above-mentioned prescription medical material mixed powder is broken to 24 sieve mesh coarse powder; Coarse powder is added 2 times of water logging bubbles 1 hour; Extract distillate with the conventional way of distillation, press the decocting method operation again, decocted 1 hour at every turn, decoct 2 times; Also available " multi-function extractor " produced distillate according to a conventional method and fried in shallow oil soup; After will frying in shallow oil soup and leaving standstill filter just, make with supercentrifugal process and to fry in shallow oil the soup purification; With distillate with fry in shallow oil soup and concentrate the concentration reach each everyone dose 20ml respectively; Dosing: with the distillate after concentrating with fry in shallow oil soup and add suitable antiseptic, antioxidant, correctives and solubilizing agent; The timely fill of the medicinal liquid for preparing in aseptic clean dried easy-open lid bottle (20ml/ props up), is added a cover obturation, 100 ℃ of flowing steam sterilization 30min.Make oral liquid.
Claims (7)
1. the medicine of a blood sugar lowering, blood fat reducing, blood pressure lowering, raising blood flow and immunity is characterized in that it is the medicament of being made by the following weight proportion raw material
Radix Ginseng 10-30 part Cortex Lycii 10-25 part Rhizoma Polygonati 20-40 part
Radix Ophiopogonis 10-20 part Fructus Lycii 10-25 part Rhizoma Atractylodis Macrocephalae 10-25 part
Fructus Ligustri Lucidi 15-25 part Radix Et Caulis Acanthopanacis Senticosi 20-50 part Rhizoma Atractylodis 10-20 part
Radix Salviae Miltiorrhizae 10-20 part
2. according to the described medicine of claim 1., wherein the weight proportion of each raw material is
Radix Ginseng 3-10 part Cortex Lycii 6-15 part Rhizoma Polygonati 10-30 part
Radix Ophiopogonis 5-15 part Fructus Lycii 6-15 part Rhizoma Atractylodis Macrocephalae 8-15 part
Fructus Ligustri Lucidi 10-20 part Radix Et Caulis Acanthopanacis Senticosi 10-45 part Rhizoma Atractylodis 5-15 part
Radix Salviae Miltiorrhizae 5-15 part
3. according to the described medicine of claim 1., wherein the weight proportion of each raw material is
13 parts of 8 parts of Rhizoma Polygonatis of 10 parts of Cortex Lycii of Radix Ginseng
8 parts of 8 parts of Rhizoma Atractylodis Macrocephalaes of 10 parts of Fructus Lycii of Radix Ophiopogonis
11 parts of 22 parts of Rhizoma Atractylodis of 10 parts of Radix Et Caulis Acanthopanacis Senticosis of Fructus Ligustri Lucidi
10 parts of Radix Salviae Miltiorrhizaes
According to claim 1., 2. or 3. described medicines, it is characterized in that said medicament is the above dosage form of saying of any pharmaceutics.
5. according to the described medicine of claim 4., it is characterized in that said medicament is mixture or oral liquid.
6. the preparation method of the described medicine of claim 5., it is characterized in that getting Radix Ginseng, Cortex Lycii, Rhizoma Polygonati, Radix Ophiopogonis, Fructus Lycii, the Rhizoma Atractylodis Macrocephalae, Fructus Ligustri Lucidi, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Atractylodis, Radix Salviae Miltiorrhizae mixed powder and be broken to coarse powder, extract distillate with the conventional way of distillation, extract by decocting method again and fry in shallow oil soup, distillate and fry in shallow oil soup respectively concentrated and purified after, fit in medicinal liquid, formulation method is prepared into oral liquid routinely.
7. according to the preparation method of the described medicine of claim 6., it is characterized in that producing distillate according to a conventional method and frying in shallow oil soup with " multi-function extractor ".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510068659 CN1853702A (en) | 2005-04-26 | 2005-04-26 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510068659 CN1853702A (en) | 2005-04-26 | 2005-04-26 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1853702A true CN1853702A (en) | 2006-11-01 |
Family
ID=37194354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510068659 Pending CN1853702A (en) | 2005-04-26 | 2005-04-26 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1853702A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641121A (en) * | 2011-02-16 | 2012-08-22 | 浙江中医药大学 | New technology for evaluating efficacy of antihypertensive traditional Chinese medicines (TCMs) |
| CN103623238A (en) * | 2012-08-28 | 2014-03-12 | 张桂林 | Diabetes treatment traditional Chinese medicine and preparation method thereof |
| CN103652193A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Health-care tea for diabetics |
| CN103989820A (en) * | 2014-06-17 | 2014-08-20 | 刘青振 | Medicament for treating hyperlipidemia |
| CN104474259A (en) * | 2014-11-13 | 2015-04-01 | 成都华熹科技有限公司 | Saffron-containing traditional Chinese medicinal composition for enhancing immunity |
| CN105434681A (en) * | 2015-12-24 | 2016-03-30 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine health-care preparation for reducing blood lipid |
-
2005
- 2005-04-26 CN CN 200510068659 patent/CN1853702A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641121A (en) * | 2011-02-16 | 2012-08-22 | 浙江中医药大学 | New technology for evaluating efficacy of antihypertensive traditional Chinese medicines (TCMs) |
| CN103623238A (en) * | 2012-08-28 | 2014-03-12 | 张桂林 | Diabetes treatment traditional Chinese medicine and preparation method thereof |
| CN103623238B (en) * | 2012-08-28 | 2015-09-02 | 张桂林 | A kind of Chinese medicine for the treatment of diabetes and preparation method thereof |
| CN103652193A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Health-care tea for diabetics |
| CN103652193B (en) * | 2013-12-11 | 2015-06-03 | 衣艳 | Health-care tea for diabetics |
| CN103989820A (en) * | 2014-06-17 | 2014-08-20 | 刘青振 | Medicament for treating hyperlipidemia |
| CN104474259A (en) * | 2014-11-13 | 2015-04-01 | 成都华熹科技有限公司 | Saffron-containing traditional Chinese medicinal composition for enhancing immunity |
| CN105434681A (en) * | 2015-12-24 | 2016-03-30 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine health-care preparation for reducing blood lipid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN1151800C (en) | Medicine for curing diabetic peripheral neuropathy | |
| CN1853702A (en) | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method | |
| CN1939506B (en) | Preparation with blood-pressure, blood-sugar and blood-fat lowering functions and its making method | |
| CN101496894B (en) | Medicine for treating fatty liver and preparation method thereof | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN1149097C (en) | Chinese patent medicine for curing diabetes | |
| CN1957972A (en) | Composition in use for invigorating primordial energy, benefiting pubic region, preparation method and usage | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN1520831A (en) | Health-preserving liver-protecting drug and method for making same | |
| CN1565524A (en) | Medicine for treating senile dementia and its preparing process | |
| CN1430982A (en) | Capsule of astragalus and honey as well as its preparing technique | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN105920371A (en) | Ganoderma lucidum compound preparation effective in lowering 'three highs' | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN102614271A (en) | Chinese medicine for treating diabetic dyslipidemia | |
| CN111000969A (en) | Pharmaceutical composition for treating simple obesity and preparation method thereof | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1088450A (en) | The excellent blood fat reducing of preparation of treatment hyperlipidemia | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |